{"id":"W2111879300","doi":"10.1634/theoncologist.2010-0081","title":"A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; BC Cancer Agency; AstraZeneca","keywords":"Pazopanib; Medicine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Oncology; Neutropenia; Progressive disease; Breast cancer; Progression-free survival; Chemotherapy; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Sunitinib","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003131394,0.0001659407,0.0003046944,0.00002500033,0.000129802,0.00000657532,0.0004271243,0.00006574669,0.00003067952],"category_scores_gemma":[0.0001394025,0.00007863723,0.00008797093,0.000157655,0.000409742,0.00000459705,0.0003117405,0.0001343463,2.40837e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002249271,"about_ca_system_score_gemma":0.0003552149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001842507,"about_ca_topic_score_gemma":0.002178647,"domain_scores_codex":[0.9987919,0.0001703002,0.0003764971,0.0002649813,0.0002113321,0.0001849497],"domain_scores_gemma":[0.9988276,0.00004434923,0.000422153,0.000503502,0.0001625511,0.00003982876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.356763,0.2247823,0.2992721,0.0001878149,0.001257071,0.00003890344,0.006671456,0.00004566554,0.06944273,0.000154579,0.002248741,0.03913571],"study_design_scores_gemma":[0.4558042,0.3260803,0.1629434,0.0000891001,0.0007783699,0.00001766844,0.004114299,0.00002364229,0.04773837,0.000030789,0.001703279,0.000676583],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974599,0.00004874555,0.000005024342,0.0001255285,0.0003320931,0.001770403,0.0001943269,0.000002784012,0.00006120245],"genre_scores_gemma":[0.9995776,0.00001078063,0.00003379297,0.00003466466,0.00007785701,0.0001649579,0.00002983622,0.00001338966,0.00005708184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1363287,"threshold_uncertainty_score":0.3206733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02070113788703112,"score_gpt":0.3093775970581596,"score_spread":0.2886764591711286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}